AD80, a multikinase inhibitor, as a potential drug candidate for colorectal cancer therapy (2022)
Source: Life Sciences. Unidade: ICB
Subjects: FARMACOLOGIA, NEOPLASIAS COLORRETAIS, PROTEÍNAS PROTO-ONCOGÊNICAS, RNA MENSAGEIRO, APOPTOSE, ANTINEOPLÁSICOS, CÉLULAS CULTIVADAS DE TUMOR, INIBIDORES DE ENZIMAS, ATIVAÇÃO ENZIMÁTICA, PROTEÍNAS QUINASES, TRANSDUÇÃO DE SINAL CELULAR, CARCINOGÊNESE, PROLIFERAÇÃO CELULAR
ABNT
ALMEIDA, Larissa Costa de et al. AD80, a multikinase inhibitor, as a potential drug candidate for colorectal cancer therapy. Life Sciences, v. 308, p. 1-9, 2022Tradução . . Disponível em: https://doi.org/10.1016/j.lfs.2022.120911. Acesso em: 16 nov. 2024.APA
Almeida, L. C. de, Carlos, J. A. E. G., Teixeira, P. R., Machado Neto, J. A., & Costa-Lotufo, L. V. (2022). AD80, a multikinase inhibitor, as a potential drug candidate for colorectal cancer therapy. Life Sciences, 308, 1-9. doi:10.1016/j.lfs.2022.120911NLM
Almeida LC de, Carlos JAEG, Teixeira PR, Machado Neto JA, Costa-Lotufo LV. AD80, a multikinase inhibitor, as a potential drug candidate for colorectal cancer therapy [Internet]. Life Sciences. 2022 ; 308 1-9.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.lfs.2022.120911Vancouver
Almeida LC de, Carlos JAEG, Teixeira PR, Machado Neto JA, Costa-Lotufo LV. AD80, a multikinase inhibitor, as a potential drug candidate for colorectal cancer therapy [Internet]. Life Sciences. 2022 ; 308 1-9.[citado 2024 nov. 16 ] Available from: https://doi.org/10.1016/j.lfs.2022.120911